High-dose intravenous melphalan for plasma-cell leukaemia and myeloma
- PMID: 6137651
- DOI: 10.1016/s0140-6736(83)90739-0
High-dose intravenous melphalan for plasma-cell leukaemia and myeloma
Abstract
1 previously untreated patient with plasma-cell leukaemia and 8 patients with myeloma (4 previously untreated) were treated with high-dose melphalan 100-140 mg/m2 iv. All responded to treatment. 3 of the 5 previously untreated patients achieved biochemical and bone-marrow complete remissions.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
